Overview
- SciNeuro announced an exclusive global licensing and collaboration with Novartis to advance its amyloid‑beta antibody program for Alzheimer’s disease.
- SciNeuro will receive $165 million upfront and is eligible for up to $1.5 billion in development, regulatory, and commercial milestones, plus tiered royalties.
- Both companies will work together in early development before Novartis assumes global clinical development and commercialization responsibilities.
- The antibodies incorporate a proprietary blood–brain barrier shuttle designed to boost brain exposure and potentially set them apart from current amyloid‑targeting drugs.
- The agreement remains subject to the Hart–Scott–Rodino waiting period and other customary conditions, as rivals also pursue brain‑shuttle strategies such as Roche’s trontinemab now in late‑stage trials.